Actively Recruiting
Evaluating Early Versus Delayed Direct Oral Anticoagulants After Emergency Endovascular Therapy for Acute Ischemic Stroke with Atrial Fibrillation
Led by Capital Medical University · Updated on 2026-09-15
240
Participants Needed
37
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of starting direct oral anticoagulants DOACs early versus later in patients who have acute ischemic stroke caused by atrial fibrillation and who develop bleeding complications after emergency endovascular treatment. This multicenter, prospective, open-label, randomized controlled trial aims to determine the best timing to initiate DOAC therapy to balance stroke recurrence and bleeding risks. Participants are assigned to one of two groups one begins any DOAC within 4 weeks after stroke onset early initiation, and the other starts DOACs between 4 and 8 weeks after stroke onset delayed initiation. The trial compares these two timing strategies following emergency endovascular therapy to see which approach is safer and more effective. During the study, participants will be monitored for outcomes including recurrent ischemic stroke, symptomatic brain bleeding, and death over 90 days. Additional assessments include quality of life, functional recovery, vascular events, and bleeding complications up to one year. Researchers will track hospital stay length and use clinical scales such as the modified Rankin Scale and EQ-5D-5L questionnaire to evaluate recovery and health status. The total study duration spans the treatment and follow-up periods up to one year.
CONDITIONS
Brief Title
Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2
Research Team
X
Xunming Ji
C
Chuanjie Wu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here